Last reviewed · How we verify
NCT05370196
Synthetic Male Condom Slippage-Breakage Study
NA trial testing Test Product in Contraceptive in 600 participants. Completed in 12 May 2023.
13 January 2023
Quick facts
| Lead sponsor | Church & Dwight Company, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 600 |
| Start date | 10 June 2022 |
| Primary completion | 13 January 2023 |
| Estimated completion | 12 May 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Test Product — full drug profile →
- Control Product — full drug profile →
Conditions studied
- Contraceptive — all drugs for Contraceptive →
- Sexually Transmitted Diseases — all drugs for Sexually Transmitted Diseases →
Sponsor
Church & Dwight Company, Inc. — full company profile →
Who can join
Adults 18 to 45, any sex, with Contraceptive or Sexually Transmitted Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-site, double-blind, crossover, randomized phase II study to evaluate the functional performance of a synthetic male condom as compared to a marketed latex condom.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05370196
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Test Product
Trials testing the same drug.
- NCT05372900 — Nutritional Intervention to Improve Sleep Quality and Improve Next-day Mood and Cognitive Benefits · NA · completed
- NCT04466176 — A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/ · Phase 1 · completed
- NCT03975166 — A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respiren · Phase 1 · completed
- NCT04051710 — Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH · Phase 3 · completed
- NCT03820180 — A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respiren · Phase 1 · completed
Other Church & Dwight Company, Inc. trials
Trials by the same sponsor.
- NCT07419763 — Intra Oral Appliance (IOA) Model Evaluating the Efficacy of Sensitive Toothpaste · NA · completed
- NCT07419737 — Dental Plaque Prevention Efficacy of a Stannous Fluoride Toothpaste · NA · completed
- NCT07419685 — Intraoral Appliance (IOA) Model Evaluating the Efficacy of a Whitening Toothpaste · NA · completed
- NCT07425509 — Evaluation of a Stannous Fluoride Dentifrice for Control of Oral Malodor · NA · completed
- NCT07419672 — Intra Oral Application (IOA) Testing Study of a Stannous Toothpaste · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05370196 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Church & Dwight Company, Inc.
- Last refreshed: 8 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05370196.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing